Takeda announces approval of Moderna's COVID-19 vaccine in Japan
- Details
- Category: Takeda
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under article 14-3 of the Pharmaceuticals and Medical Devices Act for emergency use of Moderna's mRNA COVID-19 vaccine, TAK-919, now known as COVID-19 Vaccine Moderna Intramuscular Injection, in Japan.
Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment
- Details
- Category: Novartis
Novartis announced that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was supplied without profit to malaria-endemic countries around the globe.
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial
- Details
- Category: Sanofi
The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from COVID-19, in all adult age groups in a Phase 2 study with 722 volunteers. A global pivotal Phase 3 study is expected to start in the coming weeks.
Lilly and MiNA Therapeutics announce saRNA research collaboration
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) and MiNA Therapeutics Limited, a pioneer in RNA activation therapeutics, announced a global research collaboration to develop novel drug candidates using MiNA's proprietary small activating RNA (saRNA) technology platform.
Vaccination with Sputnik V launched in India
- Details
- Category: Business
The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) announces the launch of vaccination with the Russian Sputnik V vaccine against coronavirus in India today.
Sputnik V has become the first foreign-made vaccine that is used in India contributing to the world’s largest COVID-19 vaccination campaign.
Second-generation COVID-19 vaccine candidate, CV2CoV, demonstrates high immunogenicity against virus variants in preclinical study
- Details
- Category: Business
CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced together with its collaboration partner GSK, first preclinical data in a rat model, showing that its second-generation COVID-19 vaccine candidate, CV2CoV, induces high levels of antigen production as well as strong and dose-dependent immune responses in vaccinated animals.
Novavax Announces positive preclinical data for combination influenza and COVID-19 vaccine candidate
- Details
- Category: Business
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced data from a preclinical study of the company's combination quadrivalent seasonal flu vaccine (NanoFlu™) and COVID-19 vaccine candidate (NVX-CoV2373).
More Pharma News ...
- Pfizer and BioNTech to provide COVID-19 caccine doses for olympic athletes at the 2020 Tokyo Games
- Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries
- Moderna announces emergency use listing granted by the World Health Organization for its COVID-19 vaccine
- Novartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche's Actemra/RoActemra®
- Moderna announces additional investments to increase global supply for COVID-19 vaccine to up to 3 billion doses in 2022
- Pfizer acquires Amplyx Pharmaceuticals
- Sanofi to help manufacture Moderna COVID-19 vaccine, supporting global supply demands